stock code
688016.sh
stock code
688016.sh
technology innovation, people centric
adhering to the mission of providing trustworthy and universal access to state-of-the-art total solutions to vascular circulatory diseases, endovastec™ is committed to building a globally leading group of people centric enterprises of emerging medical technologies.
products
endovastec™ is committed to r&d, manufacturing, and sales of aortic and peripheral vascular interventional devices,and our main products are thoracic and abdominal aortic stent grafts, stent grafts in surgical operation,drug coated pta balloon catheters, and pta balloon catheters etc.
news
endovastec™ completes acquisition of european medical device company optimum medical
on august 26, 2024, shanghai microport endovascular medtech (group) co., ltd. (hereinafter referred to as “endovastec™”) announced the completion of its acquisition of 72.37% equity in its associate company optimum medical device inc. (hereinafter referred to as “optimum medical”), a european medical device company. with the closing of this transaction, optimum medical has now become a wholly-owned subsidiary of endovastec™. optimum medical owns two subsidiaries, lombard medical limited and lombard medical technologies gmbh (collectively referred to as “lombard medical”).
26 aug 2024
endovastec™ announces annual results for 2023
on 27 march, 2024, shanghai microport endovascular medtech (group) co., ltd. (endovastec™，stock code: 688016.sh) announced the annual results of endovastec™ and its subsidiaries (the company) for the 12 months ended 31 december, 2023 (the reporting period).
27 mar 2024
endovastec™ completes its first implantation of cratos™ in pre-market clinical study in the eu and japan
recently, the cratos™ branched aortic stent-graft system (cratos™), developed by endovastec™, completed its first pre-market implantation at the university hospital zurich in switzerland, as the starting of its creation clinical study. this study is instrumental for approval applications in the eu and japan.
19 mar 2024
about us
news
products
investor relations
telephone:(86) (21) 38139300
address:building #1,3399 kangxin rd., simz century medicine park, shanghai201318,p.r. china
fax:(86) (21) 33750026
©云顶国际 copyright 1998-2020, shanghai microport endovascular medtech（group）co., ltd.
internet drug information service qualification certificate no.: (hu) - non-operating -2020-0065
website record/ license no.： 
the registered trademarks of “微创", "microport" and"
" are registered trademarks of shanghai microport medical (group) co., ltd., they have been authorized to be used by shanghai microport endovascular medtech (group) co., ltd., and no other party shall use such trademarks without prior written permission thereof.
